We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





Customized Assays Assembled Using Digital Molecular Barcoding Chemistry

By LabMedica International staff writers
Posted on 31 Jul 2013
A line of General Purpose Reagents (GPRs) was developed specifically to meet the needs of translational research and clinical laboratories.

NanoString Technologies, Inc. More...
(Seattle, WA, USA), a provider of life science tools for translational research and molecular diagnostic products, announced an Early Access Program for nCounter Elements, a line of General Purpose Reagents (GPRs). The announcement was made at the annual meeting of the American Association for Clinical Chemistry (AACC) taking place in Houston (TX, USA) from July 28—August 1, 2013.

nCounter Elements GPRs enable researchers to independently develop multiplexed genomic assays, and then rapidly translate those assays into clinical diagnostics offered as laboratory developed tests.

A digital molecular barcoding chemistry, nCounter Elements allows users to assemble their own customized assays using standard sets of barcodes provided by NanoString and probes that they can purchase independently from an oligonucleotide manufacturer.

"This launch further supports NanoString's vision of helping researchers to advance their understanding of disease, and then directly apply that knowledge to molecular diagnostics," said Brad Gray, president and CEO of NanoString Technologies. "By opening our technology to laboratories developing innovative diagnostics, we can accelerate the growth of our business in clinical laboratories and reach even more patients than we could through the development of in vitro diagnostic products alone."

The nCounter Elements reagents have been registered with the US Food and Drug Administration (FDA; Silver Spring, MD, USA) as a General Purpose Reagent, and are available for use in developing Laboratory Developed Tests, pursuant to a licensing arrangement to be offered by NanoString. In addition, the highly flexible architecture of nCounter Elements enables a broad range of basic research studies where iterative design and refinement of assays are important.

Since the completion of the sequencing of the human genome, many clinically relevant biomarkers and signatures have been identified. However, it has not always been possible to validate highly multiplexed assays that can both reliably test clinical samples, such as tissue biopsies stored as Formalin-Fixed Paraffin Embedded (FFPE) samples, and be easily implemented in a clinical laboratory. With nCounter Elements GPRs, this has become possible.

The nCounter-based Prosigna Breast Cancer Prognostic Gene Signature Assay is the first in vitro diagnostic kit to be marketed through the company's diagnostics business. It has received the CE marking and it is available for use by healthcare professionals in the European Union and other countries that recognize the CE marking, and in which Prosigna is registered; it is pending 510(k) clearance with the FDA and is not yet available for sale in the United States.

Related Links:
NanoString Technologies, Inc.
Food and Drug Administration



Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Uric Acid Meter
PA-16
New
Toxoplasma Gondii Test
Toxo IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New automated lab procedures can detect opioids in tiny amounts of blood (Photo courtesy of Tripathi Lab/Brown University)

First-Of-Its-Kind Quantitative Method Assesses Opioid Exposure in Newborns

As the opioid crisis continues to impact communities across the United States, laboratories encounter significant difficulties in accurately detecting opioid substances in individuals with opioid use disorder.... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: T cell immunity could be a marker for early Parkinson’s treatment (Photo courtesy of Shutterstock)

T Cells in Blood Can Detect Parkinson's Years Before Diagnosis

Diagnosing Parkinson’s disease before the appearance of motor symptoms remains one of neurology’s most significant challenges. Patients can go years—even decades—without a diagnosis, as subtle early indicators... Read more

Microbiology

view channel
Image: A prototype of the lateral flow test (Photo courtesy of University of Exeter)

POC Lateral Flow Test Detects Deadly Fungal Infection Faster Than Existing Techniques

Diagnosing mucormycosis—an aggressive and often deadly fungal infection—remains a major challenge due to the disease’s rapid progression and the lack of fast, accurate diagnostic tools. The problem became... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.